Table 2.
Outcome | RER | One-Year Survival (%) | Three-Year Survival (%) | Five-Year Survival (%) | ||||
---|---|---|---|---|---|---|---|---|
Time Period | 2007–13 vs 2000–06 | Adjusted P-value | 2000–2006 | 2007–2013 | 2000–2006 | 2007–2013 | 2000–2006 | 2007–2013 |
All patients | 0.76 (0.69–0.83) | <0.001 | 31 (28–34) | 41 (38–43) | 5 (3–6) | 8 (6–9) | 2 (1–3) | 3 (2–4) |
≤70 y | 0.74 (0.67–0.82) | <0.001 | 39 (35–42) | 49 (46–53) | 6 (4–8) | 9 (7–12) | 3 (2–4) | 4 (2–6) |
>70 y | 0.82 (0.68–0.98) | 0.053 | 8 (5–13) | 16 (12–20) | 1 (0–4) | 3 (1–5) | 1 (0–3) | 1 (0–3) |
Age groups | ||||||||
18–40 y | 0.92 (0.57–1.48) | 0.735 | 64 (48–77) | 68 (52–80) | 24 (12–37) | 22 (11–36) | 12 (4–24) | 15 (6–29) |
41–50 y | 0.70 (0.53–0.92) | 0.021 | 49 (39–58) | 70 (60–78) | 11 (6–17) | 16 (10–24) | 4 (2–9) | 6 (2–12) |
51–60 y | 0.70 (0.59–0.83) | <0.001 | 40 (35–46) | 53 (47–58) | 3 (2–6) | 8 (5–12) | 1 (1–4) | 3 (2–6) |
61–70 y | 0.78 (0.66–0.92) | 0.007 | 31 (25–37) | 37 (32–42) | 4 (2–7) | 7 (4–10) | 2 (1–4) | 2 (1–5) |
71–80 y | 0.83 (0.68–1.01) | 0.092 | 10 (6–15) | 18 (14–23) | 1 (0–5) | 3 (1–6) | 1 (0–4) | 1 (0–3) |
>80 y | 0.78 (0.51–1.20) | 0.335 | 3 (0–13) | 4 (1–12) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–0) |
Sex and age | ||||||||
Men | 0.79 (0.70–0.89) | <0.001 | 34 (31–38) | 42 (38–45) | 5 (3–7) | 7 (5–9) | 3 (1–4) | 2 (1–5) |
≤70 | 0.80 (0.70–0.92) | 0.004 | 43 (38–47) | 49 (45–54) | 6 (4–9) | 8 (6–11) | 3 (2–5) | 2 (1–4) |
>70 | 0.75 (0.58–0.97) | 0.048 | 6 (3–12) | 16 (11–23) | 1 (0–5) | 3 (1–7) | 1 (0–5) | 1 (0–5) |
Women | 0.71 (0.61–0.82) | <0.001 | 26 (22–31) | 39 (35–43) | 4 (2–6) | 9 (6–12) | 1 (1–3) | 4 (2–6) |
≤70 | 0.64 (0.54–0.76) | <0.001 | 33 (27–38) | 49 (43–54) | 5 (3–8) | 12 (8–15) | 2 (1–4) | 5 (3–9) |
>70 | 0.88 (0.68–1.15) | 0.400 | 11 (6–19) | 16 (10–22) | 1 (0–7) | 3 (1–6) | 0 (0–0) | 0 (0–0) |
Relative excessive risk of death (RER) for patients with diagnoses glioblastoma in 2007–2013 compared with diagnoses in 2000–2006. RER less than 1 indicates that patients diagnosed in 2007–2013 had a lower excess risk of death compared with patients diagnosed in 2000–2006 and vice versa.
The estimates are age-standardized and can be compared between the two periods.
One-year, 3-year and 5-year survival rates are shown as percentages with 95% confidence intervals.
Adjusted P-values refer to P-values adjusted for multiple testing.
Data from the Finnish Cancer Registry.